Single-B Cell Sorting based Pet Antibody Discovery Service

Creative Biolabs' Single-B Cell pet therapeutic antibody discovery service helps you accelerate the development of innovative veterinary biologics. We empower you to obtain high-affinity, species-specific therapeutic antibodies for companion animals. Our approach leverages advanced single B-cell screening and antibody engineering platforms, significantly reducing timelines, and enhancing the translational success of your projects by delivering candidates optimized for canine and feline systems.

Introduction

Creative Biolabs provides an end-to-end solution, delivering therapeutic antibody candidates specifically tailored for veterinary applications. We address the critical challenge of discovering potent, functional antibodies while minimizing potential immunogenicity in dogs and cats. Our platform excels at isolating rare, high-affinity antibodies from optimized immune repertoires (sourced from species like mice, rats, or rabbits) and subsequently engineering them for optimal performance and safety in the target pet species through caninization or felinization. We provide you with sequences, purified antibodies, and comprehensive data packages ready for the next stage of development.

Request a Consultation

Single-B Cell Antibody Discovery Workflow

Our streamlined process is designed for speed and quality, ensuring a clear path from project initiation to final deliverables.

Single-B Cell Sorting Pet Antibody Discovery Workflow. (Creative Biolabs Original)Fig.1 Single-B Cell Sorting-based Pet Antibody Discovery Workflow. (Creative Biolabs Original)

  • Required Starting Materials
  • Detailed information about the target antigen (e.g., protein sequence, structure, or cell line expressing the target).
  • Specific criteria for the desired antibody (e.g., target affinity, blocking/neutralizing activity, cross-reactivity requirements).
  • Intended target species (canine or feline) and application.
Key Steps Description
1. Immunization We design a custom immunization strategy using appropriate host animals (typically mice or rabbits) to generate a robust B-cell response against your target antigen.
2. Single B-Cell Isolation and Screening Utilizing advanced flow cytometry (FACS) or other sorting technologies, we isolate individual antigen-specific B cells from the immunized animals. These cells are screened using high-throughput methods to identify those producing antibodies with the desired characteristics.
3. Antibody Gene Recovery and Cloning We rescue the heavy and light chain gene pairs from selected single B cells using RT-PCR and clone them into expression vectors, preserving the natural pairing.
4. Recombinant Expression & Characterization Antibodies are expressed recombinantly (often in mammalian systems) and undergo rigorous characterization, including binding affinity (ELISA, SPR), specificity (FACS), and functional activity assays.
5. Antibody Engineering (Caninization/Felinization) Lead candidates undergo a specialized engineering process. We graft the Complementarity Determining Regions (CDRs) onto carefully selected canine or feline antibody frameworks, followed by optimization to retain affinity and minimize immunogenicity.
Final Deliverables Upon project completion, you will receive:
  • Sequences of the final caninized/felinized antibody candidates.
  • Research-grade quantities of purified recombinant antibodies.
  • A comprehensive report detailing the discovery process, characterization data (affinity, specificity, functional assays), and engineering steps.

Why Choose Us?

  • Advanced Single-Cell Screening
    We utilize cutting-edge microfluidics and FACS technology to rapidly screen millions of B cells. This high-throughput approach allows us to identify rare antibody-producing cells with desired specificities in record time.
  • Native VH - VL Pairing Preservation
    Our platform directly recovers the natural heavy (VH) and light (VL) chain pairs from individual B cells. This ensures that the resulting antibodies maintain their original high affinity and biological function, a critical factor often lost in other methods.
  • Targeted Pet Antibody Engineering
    We possess deep expertise in caninization and felinization processes, grafting CDRs onto optimized canine and feline frameworks. This significantly reduces immunogenicity risks while preserving the antibody's potency in the target companion animal species.
  • Streamlined Discovery-to-Development Pipeline
    Our integrated workflow connects seamless single B-cell discovery with efficient recombinant expression and comprehensive characterization. This provides a faster, more direct path from initial hit identification to a well-characterized, engineered therapeutic candidate ready for further development.

Creative Biolabs Authorized)

Related Services

To complement our single-B cell sorting based pet antibody discovery service and support your complete research pipeline, Creative Biolabs also offers:

Creative Biolabs Authorized)Phage Display Antibody Discovery

For alternative discovery routes and unique antibody formats.

Creative Biolabs Authorized)Hybridoma Antibody Discovery for Pets

A classic and reliable method for monoclonal antibody generation.

Creative Biolabs Authorized)Antibody Characterization

Comprehensive biophysical and functional characterization of your antibody candidates.

Creative Biolabs Authorized)Antibody Engineering

Tailoring antibodies for optimal performance and reduced immunogenicity in specific species.

Creative Biolabs Authorized)Pet Therapeutic Antibody Evaluation

In vitro and in vivo evaluation assays to assess pet therapeutic antibody safety and efficacy.

FAQs

1. What are the main advantages of Creative Biolabs' Single-B Cell platform for pet antibody discovery compared to traditional methods like hybridoma?
Our Single-B Cell platform is significantly faster, often yielding candidates in weeks versus months. It allows for the discovery of antibodies from a broader range of B-cells, including those that may not efficiently form hybridomas. Crucially, it preserves the natural pairing of heavy and light antibody chains, often resulting in antibodies with higher affinity and better developability characteristics for canine or feline.
2. How do you ensure the antibodies discovered will be therapeutic in pets?
Beyond initial discovery, we focus on characteristics crucial for therapeutic success. This includes high affinity and specificity, and importantly, species-specific engineering (caninization/felinization) to minimize immunogenicity and maximize efficacy in the target pet species. We also offer downstream services such as in vitro and in vivo evaluation to further validate therapeutic potential. We recommend discussing your specific therapeutic goals with our experts.

Partner with Creative Biolabs

Creative Biolabs is committed to advancing animal health through innovative antibody discovery solutions. Our Single-B cell sorting pet antibody discovery platform, combined with our comprehensive suite of related services and deep scientific expertise, provides a powerful engine for developing the next generation of veterinary medicines. We empower our clients to bring effective and safe antibody-based therapies to pets faster. Ready to accelerate your pet therapeutic antibody project with single-B cell sorting technology?

Please contact our experts to discuss your specific requirements and how we can help you achieve your research goals.

Contact Our Team

Services

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.